OrbiMed’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

OrbiMed’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-551,500	Closed	-$12.4M	–	147
2016 Q4	$12.4M	Buy	551,500 +180,600	+49%	+$3.53M	0.16%	82
2016 Q3	$8.42M	Hold	370,900	–	–	0.1%	106
2016 Q2	$8.75M	Sell	370,900 -467,200	-56%	-$11.5M	0.09%	98
2016 Q1	$17.1M	Sell	838,100 -463,600	-36%	-$14.7M	0.18%	67
2015 Q4	$67M	Buy	1,301,700 +317,000	+32%	+$15.4M	0.61%	46
2015 Q3	$42M	Buy	984,700 +134,000	+16%	+$6.47M	0.42%	48
2015 Q2	$38.7M	Hold	850,700	–	–	0.32%	62
2015 Q1	$32.3M	Hold	850,700	–	–	0.28%	65
2014 Q4	$24.1M	Hold	850,700	–	–	0.23%	68
2014 Q3	$21.5M	Sell	850,700 -510,900	-38%	-$13.5M	0.22%	74
2014 Q2	$39.7M	Buy	1,361,600 +403,900	+42%	+$9.78M	0.47%	49
2014 Q1	$24.8M	Hold	957,700	–	–	0.31%	58
2013 Q4	$24.7M	Buy	957,700 +630,700	+193%	+$15.3M	0.36%	57
2013 Q3	$8.75M	Sell	327,000 -153,319	-32%	-$3.65M	0.16%	81
2013 Q2	$11.8M	Buy	+480,319	New	+$9.55M	0.25%	71

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

OrbiMed's PTLA Position: Q1 2017 in Review

OrbiMed sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2017, closing a stake of 551,500 shares — an estimated $12.4M sold.

OrbiMed first reported a position in PTLA in Q2 2013 and held it in 15 quarters. The position peaked at $67M in Q4 2015. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2017.

OrbiMed reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
OrbiMed sold 551,500 Portola Pharmaceuticals, Inc. shares in Q1 2017, an estimated $12.4M.
OrbiMed first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
OrbiMed's Portola Pharmaceuticals, Inc. position peaked at $67M in Q4 2015.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2017.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.